Physician profile
Gabriel Smith
NPI 1366797144
$1,659.95
in general payments reported to CMS, 2019-2025
2 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 95% of Endodontics providers received nationally (typical 2025 total: $58.83).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.21 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,146 · Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,145.82 |
| Food and Beverage | $514.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,642.74 | 2025 | |
| Dentsply Sirona INC | $17.21 | 2023 | Aquasil Ultra+ Digit Smart Wetting Impression Material |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.